Misoprostol in the management of retained placenta, a safe alternative for manual removal? A randomised controlled trial

Misoprostol in the management of retained placenta, a safe alternative for manual removal? A randomised controlled trial - nvt

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30364

Enrollment

100

Registered

2007-08-30

Start date

2007-12-19

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retained placenta

Interventions

Will 800 micrograms of misoprostol orally.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All women with at least 25 completed pregnancy weeks and retained placenta (the placenta has not been born within 60 minutes after the birth of the child), in the abcense of postpartum haemorrhage.

Exclusion criteria

Exclusion criteria: Excessive blood loss (>1000 ml) within 60 minutes after the delivery of the newborn. Allergy for misoprostol or one of its components.

Design outcomes

Secondary

Measure	Time frame
Interval between administration of misoprostol and delivery of the placenta, placenta captiva. Possible side effects of misoprostol; diarrhoea, abdominal pain, nausea, dyspepsia, vomiting, headache and dizziness.	—

Primary

Measure	Time frame
Number of manual removals and amount of blood loss.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)